Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations
Authors
Keywords
Multiple sclerosis, Autoimmunity, Alemtuzumab, Thyroid disorder, Immune thrombocytopenia, Nephropathy
Journal
JOURNAL OF NEUROLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-03-10
DOI
10.1007/s00415-018-8822-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
- (2017) Tjalf Ziemssen et al. Therapeutic Advances in Neurological Disorders
- Factitious Graves' Disease Due to Biotin Immunoassay Interference—A Case and Review of the Literature
- (2016) Marianne S. Elston et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
- (2016) Gavin Giovannoni et al. NEUROLOGY
- More on Biotin Treatment Mimicking Graves’ Disease
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management
- (2015) Moeber Mahzari et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Graves' disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?
- (2014) Anthony P. Weetman CLINICAL ENDOCRINOLOGY
- Predictors of the physical impact of Multiple Sclerosis following community-based, exercise trial
- (2014) M Kehoe et al. Multiple Sclerosis Journal
- Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
- (2013) X. Zhang et al. JOURNAL OF IMMUNOLOGY
- Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
- (2013) J. L. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association
- (2012) Jeffrey Garber et al. Endocrine Practice
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing–remitting multiple sclerosis
- (2012) David Meyer et al. Multiple Sclerosis and Related Disorders
- A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
- (2011) A. Cuker et al. BLOOD
- Immune Thrombocytopenia
- (2011) A. Cuker et al. Hematology-American Society of Hematology Education Program
- The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports
- (2009) Deirdra R. Terrell et al. AMERICAN JOURNAL OF HEMATOLOGY
- International consensus report on the investigation and management of primary immune thrombocytopenia
- (2009) D. Provan et al. BLOOD
- Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
- (2008) Bruce D. Trapp et al. Annual Review of Neuroscience
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started